3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
3
Unknown
2
Not yet recruiting
2
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
6
Neoplasm Metastasis
4
Colonic Neoplasms
4
Rectal Neoplasms
3
Stomach Neoplasms
2
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Disease Progression
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Bile Duct Neoplasms
1
Interventions
Gemcitabine
23
Cisplatin
16
pembrolizumab
6
Fluorouracil
6
pemigatinib
4
Radiotherapy
3
Oxaliplatin
3
Leucovorin
3
Drug Therapy
3
infigratinib
2
durvalumab
2
ceritinib
2
aldesleukin
2
Radiosurgery
2
Photochemotherapy
2
Nivolumab
2
Liver Transplantation
2
Dexamethasone
2
Cholangiopancreatography, Endoscopic Retrograde
2
Carboplatin
2
Capecitabine
2
trifluridine tipiracil drug combination
1
tremelimumab
1
trametinib
1
spartalizumab
1
seribantumab
1
perfluoro-2,2,2',2'-tetramethyl-4,4'-bis(1,3-dioxolane)
1
peginterferon alfa-2b
1
pazopanib
1
padeliporfin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Cholangiocarcinoma
×
Folfox protocol
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts